{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:44:32Z","timestamp":1790804672781,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jns.2024.122973","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T16:25:07Z","timestamp":1710865507000},"page":"122973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP): Case based discussion of risk factors, clinical, and therapeutic considerations"],"prefix":"10.1016","volume":"459","author":[{"given":"Lea","family":"Saab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"DiCapua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel S.","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jns.2024.122973_bb0005","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150472","article-title":"HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia\/lymphoma","volume":"131","author":"Tan","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.jns.2024.122973_bb0010","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001712","article-title":"ICTV virus taxonomy profile: Retroviridae 2021","volume":"102","author":"Coffin","year":"2021","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jns.2024.122973_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1742-4690-2-17","article-title":"The discovery of the first human retrovirus: HTLV-1 and HTLV-2","volume":"2","author":"Gallo","year":"2005","journal-title":"Retrovirology"},{"issue":"39","key":"10.1016\/j.jns.2024.122973_bb0020","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","article-title":"Global epidemiology of HTLV-I infection and associated diseases","volume":"24","author":"Proietti","year":"2005","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.jns.2024.122973_bb0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JOP.2017.021907","article-title":"Adult T-Cell Leukemia\/Lymphoma","volume":"13","author":"Mehta-Shah","year":"2017","journal-title":"J. Oncol. Pract."},{"issue":"4","key":"10.1016\/j.jns.2024.122973_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/v14040794","article-title":"Updates on HTLV-1 uveitis","volume":"14","author":"Kamoi","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.jns.2024.122973_bb0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1053\/j.semdp.2019.04.002","article-title":"Infective dermatitis: a purely cutaneous manifestation of HTLV-1 infection","volume":"37","author":"Bravo","year":"2020","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.jns.2024.122973_bb0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fmicb.2012.00389","article-title":"Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy\/tropical spastic paraparesis","volume":"3","author":"Yamano","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jns.2024.122973_bb0045","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3389\/fmicb.2017.02563","article-title":"Role of HTLV-1 tax and HBZ in the pathogenesis of HAM\/TSP","volume":"8","author":"Enose-Akahata","year":"2017","journal-title":"Front. Microbiol."},{"issue":"8","key":"10.1016\/j.jns.2024.122973_bb0050","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1007\/s00115-012-3565-y","article-title":"HTLV-1-associated myelopathy\/tropical spastic paraparesis: a differential diagnosis in multiple sclerosis","volume":"83","author":"Liesz","year":"2012","journal-title":"Nervenarzt"},{"issue":"8452","key":"10.1016\/j.jns.2024.122973_bb0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","article-title":"Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis","volume":"2","author":"Gessain","year":"1985","journal-title":"Lancet"},{"issue":"8488","key":"10.1016\/j.jns.2024.122973_bb0060","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","article-title":"HTLV-I associated myelopathy, a new clinical entity","volume":"1","author":"Osame","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2024.122973_bb0065","series-title":"Scientific Group on HTLV-I Infections and Associated Diseases","author":"Organization, W.H","year":"1988"},{"key":"10.1016\/j.jns.2024.122973_bb0070","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3389\/fmicb.2020.01151","article-title":"A strategy for screening and confirmation of HTLV-1\/2 infections in low-endemic areas","volume":"11","author":"Ji","year":"2020","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.jns.2024.122973_bb0075","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1128\/JVI.74.5.2178-2185.2000","article-title":"Characterization and sequencing of prototypic human T-lymphotropic virus type 1 (HTLV-1) from an HTLV-1\/2 seroindeterminate patient","volume":"74","author":"Waziri","year":"2000","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.jns.2024.122973_bb0080","first-page":"205","article-title":"The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown","volume":"11","author":"Hlela","year":"2009","journal-title":"AIDS Rev."},{"issue":"5","key":"10.1016\/j.jns.2024.122973_bb0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/aid.1993.9.381","article-title":"An HTLV-I vaccine: why, how, for whom?","volume":"9","author":"de The","year":"1993","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.jns.2024.122973_bb0090","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front. Microbiol."},{"issue":"6","key":"10.1016\/j.jns.2024.122973_bb0095","first-page":"485","article-title":"HTLV-1 infection: an emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases","volume":"32","author":"Eusebio-Ponce","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"issue":"11","key":"10.1016\/j.jns.2024.122973_bb0100","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1212\/01.WNL.0000096011.92542.DA","article-title":"Prevalence and clinical features of HTLV neurologic disease in the HTLV outcomes study","volume":"61","author":"Orland","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.122973_bb0105","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3389\/fmicb.2019.01101","article-title":"Association between HTLV-1 genotypes and risk of HAM\/TSP","volume":"10","author":"Saito","year":"2019","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.jns.2024.122973_bb0110","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1128\/JCM.42.5.2020-2026.2004","article-title":"High seroprevalence of human T-cell lymphotropic virus type 1 in blood donors in Guyana and molecular and phylogenetic analysis of new strains in the Guyana shelf (Guyana, Suriname, and French Guiana)","volume":"42","author":"Pouliquen","year":"2004","journal-title":"J. Clin. Microbiol."},{"issue":"5","key":"10.1016\/j.jns.2024.122973_bb0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/vox.12778","article-title":"The prevalence of human T-lymphotropic virus type 1 & 2 (HTLV-1\/2) in south African blood donors","volume":"114","author":"Vermeulen","year":"2019","journal-title":"Vox Sang."},{"issue":"1","key":"10.1016\/j.jns.2024.122973_bb0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00007890-200301150-00019","article-title":"Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor","volume":"75","author":"Toro","year":"2003","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jns.2024.122973_bb0125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJM199002083220607","article-title":"Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation","volume":"322","author":"Gout","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2024.122973_bb0130","first-page":"520","article-title":"Neurologic, clinical, and immunologic features in a cohort of HTLV-1 carriers with high proviral loads","volume":"26","author":"Ferraz","year":"2020","journal-title":"J. Neuro-Oncol."},{"issue":"6","key":"10.1016\/j.jns.2024.122973_bb0135","first-page":"586","article-title":"Analysis of HTLV-I proviral load in 202 HAM\/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM\/TSP","volume":"4","author":"Nagai","year":"1998","journal-title":"J. Neuro-Oncol."},{"issue":"7","key":"10.1016\/j.jns.2024.122973_bb0140","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/jmv.22087","article-title":"Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients according to new diagnostic criteria of HAM\/TSP","volume":"83","author":"Grassi","year":"2011","journal-title":"J. Med. Virol."},{"issue":"10","key":"10.1016\/j.jns.2024.122973_bb0145","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1089\/aid.2006.22.931","article-title":"Proposal for diagnostic criteria of tropical spastic paraparesis\/HTLV-I-associated myelopathy (TSP\/HAM)","volume":"22","author":"De Castro-Costa","year":"2006","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.jns.2024.122973_bb0150","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/478461","article-title":"Immunogenetics and the pathological mechanisms of human T-cell leukemia VirusType 1- (HTLV-1-)associated myelopathy\/tropical spastic Paraparesis (HAM\/TSP)","volume":"2010","author":"Saito","year":"2010","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"10.1016\/j.jns.2024.122973_bb0155","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3389\/fmicb.2016.01674","article-title":"Family aggregation of human T-Lymphotropic virus 1-associated diseases: a systematic review","volume":"7","author":"Alvarez","year":"2016","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.jns.2024.122973_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006304","article-title":"Temporal trends in human T-Lymphotropic virus 1 (HTLV-1) associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) incidence in Martinique over 25 years (1986-2010)","volume":"12","author":"Olindo","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jns.2024.122973_bb0165","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2016.10.030","article-title":"HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP): a comparative study to identify factors that influence disease progression","volume":"371","author":"Matsuura","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.122973_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737941","article-title":"Following the clues: usefulness of biomarkers of Neuroinflammation and neurodegeneration in the investigation of HTLV-1-associated myelopathy progression","volume":"12","author":"Souza","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2024.122973_bb0175","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3389\/fmicb.2018.01651","article-title":"Proposal of classification criteria for HTLV-1-associated myelopathy\/tropical spastic Paraparesis disease activity","volume":"9","author":"Sato","year":"2018","journal-title":"Front. Microbiol."},{"issue":"6","key":"10.1016\/j.jns.2024.122973_bb0180","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1590\/S0037-86822010000600013","article-title":"Mielopatia associada ao HTLV-1: an\u00e1lise clinico-epidemiol\u00f3gica em uma s\u00e9rie de casos de 10 anos","volume":"43","author":"Champs","year":"2010","journal-title":"Rev. Soc. Bras. Med. Trop."},{"issue":"1","key":"10.1016\/j.jns.2024.122973_bb0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41687-020-00198-6","article-title":"Signs, meanings and practices of people living with human t-cell lymphotropic virus type 1 or tropical spastic myelopathy","volume":"4","author":"Santana","year":"2020","journal-title":"J. Patient Rep. Outcom."},{"key":"10.1016\/j.jns.2024.122973_bb0190","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jns.2017.08.3243","article-title":"Spinal cord anteroposterior atrophy in HAM\/TSP: magnetic resonance imaging and neuropathological analyses","volume":"381","author":"Taniguchi","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2024.122973_bb0195","first-page":"428","article-title":"Khorasan disease: prevalence of HTLV-I associated myelopathy\/tropical spastic Paraparesis (HAM\/TSP) in West Azarbaijan from 2004 to 2007","volume":"13","author":"Boostani","year":"2011","journal-title":"Iran Red Crescent Med J"},{"issue":"5","key":"10.1016\/j.jns.2024.122973_bb0200","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1440-1789.2010.01135.x","article-title":"Neuropathology of HTLV-1-associated myelopathy (HAM\/TSP): The 50th anniversary of Japanese Society of Neuropathology","volume":"30","author":"Izumo","year":"2010","journal-title":"Neuropathology"},{"issue":"10","key":"10.1016\/j.jns.2024.122973_bb0205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.5435\/JAAOS-D-14-00219","article-title":"Spinal cord blood supply and its surgical implications","volume":"23","author":"Colman","year":"2015","journal-title":"J. Am. Acad. Orthop. Surg."},{"issue":"1","key":"10.1016\/j.jns.2024.122973_bb0210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-0404.1993.tb04188.x","article-title":"Clinical and demographic features of HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) in Rio de Janeiro, Brazil","volume":"88","author":"Araujo Ade","year":"1993","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.jns.2024.122973_bb0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000008063","article-title":"Sensory dysfunction in HTLV-I-associated myelopathy\/tropical spastic paraparesis. A comprehensive neurophysiological study","volume":"42","author":"Castillo","year":"1999","journal-title":"Eur. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2024.122973_bb0220","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/archneur.63.11.1560","article-title":"Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study","volume":"63","author":"Olindo","year":"2006","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.122973_bb0225","first-page":"50","article-title":"HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings","volume":"1","author":"Nakagawa","year":"1995","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jns.2024.122973_bb0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13023-016-0451-x","article-title":"Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net)","volume":"11","author":"Coler-Reilly","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.jns.2024.122973_bb0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1212\/CPJ.0000000000000832","article-title":"Management of HAM\/TSP: systematic review and consensus-based recommendations 2019","volume":"11","author":"Araujo","year":"2021","journal-title":"Neurol. Clin. Pract"},{"issue":"3","key":"10.1016\/j.jns.2024.122973_bb0240","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1212\/01.wnl.0000251300.24540.c4","article-title":"Differentiation of HAM\/TSP from patients with multiple sclerosis infected with HTLV-I","volume":"68","author":"Puccioni-Sohler","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2024.122973_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228883","article-title":"Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides","volume":"15","author":"Graner","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jns.2024.122973_bb0250","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.39.12.1566","article-title":"Chronic progressive myelopathy associated with HTLV-I: oligoclonal IgG and anti-HTLV-I IgG antibodies in cerebrospinal fluid and serum","volume":"39","author":"Link","year":"1989","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2024.122973_bb0255","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S0317167100002420","article-title":"MRI contributes to the differentiation between MS and HTLV-I associated myelopathy in British Columbian coastal natives","volume":"30","author":"Howard","year":"2003","journal-title":"Can. J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2024.122973_bb0260","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1212\/WNL.45.1.30","article-title":"Assessment of MRI criteria for MS in Japanese MS and HAM\/TSP","volume":"45","author":"Kuroda","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.122973_bb0265","first-page":"1","article-title":"Cerebral and spinal cord changes observed through magnetic resonance imaging in patients with HTLV-1-associated myelopathy\/tropical spastic paraparesis: a systematic review","volume":"28","author":"Ferreira","year":"2022","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jns.2024.122973_bb0270","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-3-63","article-title":"Zidovudine plus lamivudine in human T-Lymphotropic virus type-I-associated myelopathy: a randomised trial","volume":"3","author":"Taylor","year":"2006","journal-title":"Retrovirology"},{"issue":"10","key":"10.1016\/j.jns.2024.122973_bb0275","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/acn3.51437","article-title":"Clinical trial of raltegravir, an integrase inhibitor in HAM\/TSP","volume":"8","author":"Enose-Akahata","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2024.122973_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152557","article-title":"Effect of pulsed methylprednisolone on pain, in patients with HTLV-1-associated myelopathy","volume":"11","author":"Buell","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jns.2024.122973_bb0285","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s13311-017-0533-z","article-title":"Effectiveness of daily prednisolone to slow progression of human T-Lymphotropic virus type 1-associated myelopathy\/tropical spastic Paraparesis: a multicenter retrospective cohort study","volume":"14","author":"Coler-Reilly","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.jns.2024.122973_bb0290","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1704827","article-title":"Mogamulizumab (anti-CCR4) in HTLV-1-associated myelopathy","volume":"378","author":"Sato","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2024.122973_bb0295","first-page":"364","article-title":"Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy","volume":"13","author":"Arimura","year":"2007","journal-title":"J. Neuro-Oncol."},{"issue":"12","key":"10.1016\/j.jns.2024.122973_bb0300","doi-asserted-by":"crossref","DOI":"10.1089\/aid.1991.7.1031","article-title":"Tropical spastic Paraparesis\/HTLV-1-associated myelopathy (TSP\/HAM): treatment with an anabolic steroid Danazol","volume":"7","author":"Harrington","year":"1991","journal-title":"AIDS Res. Hum. Retrovir."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T08:30:22Z","timestamp":1712910622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":60,"alternative-id":["S0022510X24001084"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.122973","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP): Case based discussion of risk factors, clinical, and therapeutic considerations","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.122973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122973"}}